MA33122B1 - Molecules d'anticorps ayant une specificite pour ox40 humain - Google Patents

Molecules d'anticorps ayant une specificite pour ox40 humain

Info

Publication number
MA33122B1
MA33122B1 MA34167A MA34167A MA33122B1 MA 33122 B1 MA33122 B1 MA 33122B1 MA 34167 A MA34167 A MA 34167A MA 34167 A MA34167 A MA 34167A MA 33122 B1 MA33122 B1 MA 33122B1
Authority
MA
Morocco
Prior art keywords
antibody molecules
human
quality
specificity
producing
Prior art date
Application number
MA34167A
Other languages
Arabic (ar)
English (en)
Inventor
Alastair David Griffiths Lawson
Andrew Malcolm Nesbitt
Andrew George Popplewell
Stephen Graham Shaw
Diana Shpektor
Yi Zhang
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42634416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33122(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of MA33122B1 publication Critical patent/MA33122B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

L'invention porte sur des molécules d'anticorps ayant une spécificité pour des déterminants antigéniques de OX40 humain, sur des utilisations thérapeutiques des molécules d'anticorps et sur des procédés de production desdites molécules d'anticorps.
MA34167A 2009-02-17 2010-02-17 Molecules d'anticorps ayant une specificite pour ox40 humain MA33122B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15303809P 2009-02-17 2009-02-17
PCT/US2010/024377 WO2010096418A2 (fr) 2009-02-17 2010-02-17 Molécules d'anticorps ayant une spécificité pour ox40 humain

Publications (1)

Publication Number Publication Date
MA33122B1 true MA33122B1 (fr) 2012-03-01

Family

ID=42634416

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34167A MA33122B1 (fr) 2009-02-17 2010-02-17 Molecules d'anticorps ayant une specificite pour ox40 humain

Country Status (34)

Country Link
US (3) US8614295B2 (fr)
EP (1) EP2398498B1 (fr)
JP (2) JP5782385B2 (fr)
KR (1) KR101761929B1 (fr)
CN (1) CN102741287B (fr)
AR (1) AR075504A1 (fr)
AU (1) AU2010216152B2 (fr)
BR (1) BRPI1008692B8 (fr)
CA (1) CA2751477C (fr)
CL (1) CL2011001994A1 (fr)
CO (1) CO6410312A2 (fr)
CY (1) CY1121431T1 (fr)
DK (1) DK2398498T3 (fr)
EA (1) EA037792B1 (fr)
ES (1) ES2699716T3 (fr)
HR (1) HRP20181932T1 (fr)
HU (1) HUE042114T2 (fr)
IL (1) IL214282A (fr)
LT (1) LT2398498T (fr)
MA (1) MA33122B1 (fr)
MX (1) MX2011008697A (fr)
MY (1) MY157473A (fr)
NZ (1) NZ594315A (fr)
PE (1) PE20120211A1 (fr)
PL (1) PL2398498T3 (fr)
PT (1) PT2398498T (fr)
SG (3) SG173620A1 (fr)
SI (1) SI2398498T1 (fr)
TN (1) TN2011000374A1 (fr)
TW (1) TWI476281B (fr)
UA (1) UA107341C2 (fr)
UY (1) UY32451A (fr)
WO (1) WO2010096418A2 (fr)
ZA (1) ZA201105500B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2398498B1 (fr) * 2009-02-17 2018-09-05 UCB Biopharma SPRL Molécules d'anticorps ayant une spécificité pour ox40 humain
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
PL2609118T3 (pl) 2010-08-23 2017-07-31 Board Of Regents, The University Of Texas System Przeciwciała anty-OX40 i sposoby ich stosowania
JP6093712B2 (ja) 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン２のスーパーアゴニストおよびアンタゴニスト
EP2731677B1 (fr) * 2011-07-11 2018-04-18 Glenmark Pharmaceuticals S.A. Anticorps qui se lient à l'ox40 et leurs utilisations
KR101685262B1 (ko) * 2011-08-23 2016-12-21 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｏｘ４０ 항체 및 이의 사용 방법
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
SI2776466T1 (sl) * 2011-11-11 2017-12-29 Ucb Biopharma Sprl Protitelesa, ki se vežejo na albumin in njihovi vezavni fragmenti
US20130149351A1 (en) * 2011-12-09 2013-06-13 University Of Southern California Polymer scaffolds and their use in the treatment of vision loss
WO2014089113A1 (fr) 2012-12-03 2014-06-12 Bristol-Myers Squibb Company Amélioration de l'activité anticancéreuse de protéines de fusion de fc immuno-modulatrices
NZ712903A (en) * 2013-03-18 2018-07-27 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
WO2015042707A1 (fr) 2013-09-24 2015-04-02 Medicenna Therapeutics Pte Ltd Protéines hybrides de l'interleukine-2 et leurs utilisations
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
ES3040431T3 (en) * 2014-03-12 2025-10-31 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
EP3322443A1 (fr) * 2015-07-13 2018-05-23 Yeda Research and Development Co. Ltd Diminution des niveaux ou de l'activité systémiques de cellules t régulatrices pour le traitement de maladies et lésions du snc
KR101844596B1 (ko) * 2014-03-18 2018-04-05 한국과학기술원 당화 vegf 디코이 수용체 융합 단백질을 포함하는 안질환 치료용 조성물
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
WO2015164815A1 (fr) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonistes, agonistes et antagonistes partiels de l'interleukine-2
AU2015266958A1 (en) 2014-05-28 2016-12-08 Agenus Inc. Anti-GITR antibodies and methods of use thereof
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
RS63384B1 (sr) 2015-01-08 2022-08-31 BioNTech SE Agonistička sredstva za vezivanje tnf receptora
HRP20230046T1 (hr) 2015-03-03 2023-03-03 Kymab Limited Protutijela, upotreba i postupci
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
GB201506868D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
PH12017502013B1 (en) 2015-05-07 2022-07-22 Agenus Inc Anti-ox40 antibodies and methods of use thereof
UY36687A (es) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
MA43017A (fr) * 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
CN108137684B (zh) * 2015-10-15 2022-03-08 苏州丁孚靶点生物技术有限公司 抗ox40抗体及其应用
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
JP7328761B2 (ja) 2016-01-11 2023-08-17 インヒブルクス インコーポレイテッド 多価多重特異性ｏｘ４０結合融合タンパク質
WO2017134292A1 (fr) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anticorps antagonistes anti-ox40 pour le traitement de dermatites atopiques
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
EP3494139B1 (fr) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Anticorps multivalents et multiépitopiques ayant une activité agoniste et procédés d'utilisation
CN112274637A (zh) 2016-08-17 2021-01-29 康姆普根有限公司 抗tigit抗体、抗pvrig抗体及其组合
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
EP3538152A4 (fr) 2016-11-09 2020-09-30 Agenus Inc. Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
WO2018220446A1 (fr) 2017-06-01 2018-12-06 Compugen Ltd. Thérapies à base d'anticorps à triple combinaison
JP7433051B2 (ja) 2017-06-19 2024-02-19 メディシナ セラピューティクス インコーポレイテッド Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
JP2021517133A (ja) * 2018-03-08 2021-07-15 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 抗ｃｄ２５２抗体、コンジュゲート、および使用方法
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
ES3014697T3 (en) 2018-07-19 2025-04-24 Ichnos Sciences S A Liquid antibody formulation
BR112021002164A2 (pt) 2018-08-13 2021-08-03 Inhibrx, Inc. polipeptídeos de ligação a ox40 e usos dos mesmos
WO2020070288A1 (fr) 2018-10-05 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et systèmes de contrôle des propriétés agonistes de domaines variables d'un anticorps par la lumière
US10442866B1 (en) * 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof
EP3962493A2 (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
EP3766481A1 (fr) * 2019-07-19 2021-01-20 Ichnos Sciences SA Formulation d'anticorps liquides
EP4076434A1 (fr) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Polythérapies anticancéreuses ayant des inducteurs de désassemblage cellulaire dépendant du fer
CN114867749A (zh) 2019-12-17 2022-08-05 安进公司 用于疗法中的双重白介素-2/tnf受体激动剂
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
CA3214085A1 (fr) 2021-03-31 2022-10-06 Darby Rye Schmidt Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer
EP4363059A1 (fr) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Cellules immunitaires modifiées pour favoriser la thanotransmission de phényléthanolamines et leurs utilisations
WO2023064958A1 (fr) 2021-10-15 2023-04-20 Compugen Ltd. Polythérapie avec des formulations d'anticorps anti-pvrig, d'anticorps anti-tigit et d'anticorps anti-pd-1
EP4507779A1 (fr) 2022-04-14 2025-02-19 Institut National de la Santé et de la Recherche Médicale Procédés de commande de la destruction de cellules tumorales par la lumière
EP4598946A1 (fr) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
WO2024151687A1 (fr) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Commutateurs génétiques et leur utilisation dans le traitement du cancer
TW202523691A (zh) * 2023-10-06 2025-06-16 瑞士商伊克諾斯科學公司 親和力成熟之抗－ｏｘ４０抗體及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1541682A3 (fr) 1988-09-02 2005-07-06 Dyax Corp. Production et sélection de protéines de liaison diversifiées recombinantes
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (fr) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production d'anticorps utilisant des librairies de genes
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (fr) 1990-08-02 1992-02-20 B.R. Centre Limited Procedes de production de proteines presentant une fonction souhaitee
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
WO1995015982A2 (fr) 1993-12-08 1995-06-15 Genzyme Corporation Procede de generation d'anticorps specifiques
DE69531148T2 (de) 1994-01-31 2004-04-29 Trustees Of Boston University, Boston Bibliotheken aus polyklonalen antikörpern
US6242566B1 (en) * 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0123276D0 (en) 2001-09-27 2001-11-21 Imp College Innovations Ltd Uses of agents that bind immune-system components
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
WO2003059245A2 (fr) 2001-12-18 2003-07-24 J & J Research Pty Ltd Methode de traitement de l'asthme
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
US20040146948A1 (en) 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
JP4603894B2 (ja) 2002-12-03 2010-12-22 ユセベ ファルマ ソシエテ アノニム 抗体産生細胞を同定するためのアッセイ
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
AU2004253738A1 (en) 2003-07-01 2005-01-13 Ucb Pharma S.A. Modified antibody Fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CA2528903C (fr) * 2004-12-20 2008-01-15 Honda Motor Co., Ltd. Dispositif de freinage pour motocycle
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
GB0513852D0 (en) 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
US7850965B2 (en) * 2005-12-05 2010-12-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
JP2009530391A (ja) 2006-03-22 2009-08-27 インペリアル・イノベ−ションズ・リミテッド 免疫系の因子の調節に関連する組成物および方法
WO2007112054A2 (fr) 2006-03-23 2007-10-04 Sea Lane Biotechnologies, Llc Facilitation de la translocation de molecules a travers le tractus gastro-intestinal
CA2679399A1 (fr) * 2007-02-27 2008-09-04 Genetech, Inc. Anticorps antagoniste d'ox40, et leur utilisation dans le traitement de maladies inflammatoires et auto-immunes
JP5592792B2 (ja) 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
HUE032735T2 (en) 2007-12-14 2017-10-30 Bristol Myers Squibb Co Binding molecules for the human OX40 receptor
EP2398498B1 (fr) * 2009-02-17 2018-09-05 UCB Biopharma SPRL Molécules d'anticorps ayant une spécificité pour ox40 humain
ES2667258T3 (es) * 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB201000467D0 (en) * 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
EP2731677B1 (fr) * 2011-07-11 2018-04-18 Glenmark Pharmaceuticals S.A. Anticorps qui se lient à l'ox40 et leurs utilisations
UA112203C2 (uk) * 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини

Also Published As

Publication number Publication date
LT2398498T (lt) 2019-01-10
CO6410312A2 (es) 2012-03-30
SI2398498T1 (sl) 2019-02-28
TN2011000374A1 (en) 2013-03-27
ZA201105500B (en) 2012-10-31
HRP20181932T1 (hr) 2019-01-25
EA201171060A1 (ru) 2012-07-30
EP2398498A4 (fr) 2013-05-01
UY32451A (es) 2010-09-30
EP2398498A2 (fr) 2011-12-28
PT2398498T (pt) 2018-12-03
US10017575B2 (en) 2018-07-10
JP2015171362A (ja) 2015-10-01
KR101761929B1 (ko) 2017-07-26
CY1121431T1 (el) 2020-05-29
BRPI1008692B8 (pt) 2021-05-25
NZ594315A (en) 2013-05-31
SG173620A1 (en) 2011-09-29
MY157473A (en) 2016-06-15
US9428570B2 (en) 2016-08-30
SG10201505038TA (en) 2015-07-30
SG2014014708A (en) 2014-05-29
PL2398498T3 (pl) 2019-03-29
IL214282A0 (en) 2011-09-27
WO2010096418A3 (fr) 2012-06-14
TW201031753A (en) 2010-09-01
ES2699716T3 (es) 2019-02-12
UA107341C2 (uk) 2014-12-25
CL2011001994A1 (es) 2012-02-24
MX2011008697A (es) 2011-11-18
DK2398498T3 (en) 2019-01-07
CN102741287B (zh) 2015-02-18
BRPI1008692A2 (pt) 2016-03-08
KR20110128301A (ko) 2011-11-29
JP5782385B2 (ja) 2015-09-24
CA2751477C (fr) 2019-08-27
TWI476281B (zh) 2015-03-11
WO2010096418A2 (fr) 2010-08-26
US20160355598A1 (en) 2016-12-08
US20100254978A1 (en) 2010-10-07
BRPI1008692B1 (pt) 2020-10-27
EP2398498B1 (fr) 2018-09-05
US8614295B2 (en) 2013-12-24
IL214282A (en) 2017-04-30
JP2012521191A (ja) 2012-09-13
CA2751477A1 (fr) 2010-08-26
AR075504A1 (es) 2011-04-06
CN102741287A (zh) 2012-10-17
HK1177470A1 (en) 2013-08-23
AU2010216152A1 (en) 2011-08-18
HUE042114T2 (hu) 2019-06-28
AU2010216152B2 (en) 2015-05-14
PE20120211A1 (es) 2012-03-24
US20130330344A1 (en) 2013-12-12
EA037792B1 (ru) 2021-05-21

Similar Documents

Publication Publication Date Title
MA33122B1 (fr) Molecules d'anticorps ayant une specificite pour ox40 humain
MA35724B1 (fr) Molécules d'anticorps ayant une spécificité pour des déterminants antigéniques de ox40 humain, des utilisations thérapeutiques de ces molécules d'anticorps et leurs procédés de production.
MA34907B1 (fr) Molécules d'anticorps se liant à il-17a et il-17f
MY147217A (en) Antibody molecules having specificity for human il-06
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
TW200621801A (en) Antibody molecules having specificity for human IL-17
CY1118640T1 (el) Μορια αντισωματος που εχουν ειδικοτητα προσδεσης για την ανθρωπινη il-13
TR201907599T4 (tr) IL-17A ve IL-17F'yi bağlayan antikor molekülleri.
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
NZ593314A (en) Dual variable domain immunoglobulins and uses thereof
PH12014500903A1 (en) Bispecific immunobinders directed against tnf and il-17
CY1113074T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
WO2010129033A3 (fr) Anticorps modifiés pour immunothérapie passive
UA107600C2 (uk) АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ
MY160736A (en) Bivalent, bispecific antibodies
EA201300978A1 (ru) Антитела к сеа
MX2010005888A (es) Anticuerpos bivalentes biespecificos.
MY157173A (en) Modified humanised anti-interleukin-18
EP2502936A4 (fr) Mutant hautement fonctionnel de région variable d'anticorps anti-egfr humanisée
EP2569334A4 (fr) Recombinantly produced antibodies targeting erbb signaling molecules and methods of use thereof for the diagnosis and treatment of disease
JO2844B1 (en) Forms of Tyapentin sulfate salt and methods of its manufacture and use
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2
UA109423C2 (uk) Композиція та спосіб для діагностики і лікування пухлини